Pharmaceutical Research

, Volume 22, Issue 10, pp 1678–1684 | Cite as

Pharmacokinetic Differences between Pantoprazole Enantiomers in Rats

Research Paper


The purpose of this study was to quantitatively clarify the contribution of the absorption, protein binding, and metabolism of cytochrome P450 enzymes to the enantioselective pharmacokinetics of pantoprazole enantiomers in rats.


The enantioselective pharmacokinetics of pantoprazole enantiomers was estimated by an oral administration of racemic pantoprazole to rats. The pharmacokinetic differences between pantoprazole enantiomers were evaluated by the experiments of the in situ perfusion into rat small intestine, the protein binding, and the in vitro metabolism in rat liver microsomes of pantoprazole enantiomers.


The mean area under the curve value of S-pantoprazole was 1.5 times greater than that of R-pantoprazole after administration of racemic pantoprazole to rats (20 mg/kg, p.o.). There were significant differences in ke (p < 0.05), t1/2 (p < 0.01), and mean residence time (p < 0.01) values between the two enantiomers. In the in situ absorption study, the absorption rate constants were of no significant differences between the two enantiomers. The mean unbound fraction of R-pantoprazole was slightly greater than that of S-pantoprazole. The intrinsic clearance (CLint) of the formation of the 5′-O-demethyl metabolite from S-pantoprazole was 4-fold lower than that from R-pantoprazole. However, the CLint value for the sulfone and 6-hydroxy metabolites from S-pantoprazole was higher than that from R-pantoprazole. The sum of the CLint of the formation of all three metabolites was 3.06 and 4.82 mL/min/mg protein for S- and R-pantoprazole, respectively.


This study suggests that the enantioselective pharmacokinetics of pantoprazole enantiomers in rats is probably ascribable to their enantioselective metabolism, which is contributed by all the three metabolic pathways, including sulfoxide oxidation, 4′-O-demethylation, and 6-hydroxylation.

Key words

enantiomer enantioselectivity metabolism pantoprazole pharmacokinetics 



This work was supported in part by Grant 2003AA2Z347C of the “863” Program of China.


  1. 1.
    Lindberg, P., Nordberg, P., Alminger, T., Brandstrom, A., Wallmark, B. 1986The mechanism of action of the gastric acid secretion inhibitor omeprazoleJ. Med. Chem.2913271329CrossRefPubMedGoogle Scholar
  2. 2.
    Fitton, A., Wiseman, L. 1996Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disordersDrugs51460482PubMedGoogle Scholar
  3. 3.
    Jungnickel, P.W. 2000Pantoprazole: a new proton pump inhibitorClin. Ther.2212681293CrossRefPubMedGoogle Scholar
  4. 4.
    Simon, W. A. 1995Pantoprazole—Which cytochrome P450 isoenzymes are involved in its biotransformationGut37A135Google Scholar
  5. 5.
    Cairns, A. M., Chiou, R. H., Rogers, J. D., Demetriades, J. L. 1995Enantioselective high-performance liquid chromatographic determination of omeprazole in human plasmaJ. Chromatogr.666323328Google Scholar
  6. 6.
    Tybring, G., Bottiger, Y., Widen, J., Bertilsson, L. 1997Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjectsClin. Pharmacol. Ther.62129137CrossRefPubMedGoogle Scholar
  7. 7.
    Tanaka, M., Ohkubo, T., Otani, K., Suzuki, A., Kaneko, S., Sugawara, K., Ryokawa, Y., Ishizaki, T. 2001Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoinClin. Pharmacol. Ther.69108113CrossRefPubMedGoogle Scholar
  8. 8.
    Tanaka, M., Yamazaki, H., Hakusui, H., Nakamichi, N., Sekino, H. 1997Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole: a preliminary studyChirality91721CrossRefPubMedGoogle Scholar
  9. 9.
    Katsuki, H., Yagi, H., Arimori, K., Nakamura, C., Nakano, M., Katafuchi, S., Fujioka, Y., Fujiyama, S. 1996Determination of R(+)- and S(−)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humansPharm. Res.13611615CrossRefPubMedGoogle Scholar
  10. 10.
    Kim, K., Shon, J., Park, J., Yoon, Y., Kim, M., Yun, D., Kim, M., Cha, I., Hyun, M., Shin, J. 2002Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19Clin. Pharmacol. Ther.729099CrossRefPubMedGoogle Scholar
  11. 11.
    Takakuwa, S., Chiku, S., Nakata, H., Yuzuriha, T., Mano, N., Asakawa, N. 1995Enantioselective high-performance liquid chromatographic assay for determination of the enantiomers of a new anti-ulcer agent, E3810, in Beagle dog plasma and rat plasmaJ. Chromatogr., B673113122Google Scholar
  12. 12.
    Mano, N., Oda, Y., Takakuwa, S., Chiku, S., Nakata, H., Asakawa, N. 1996Plasma direct injection high-performance liquid chromatographic method for simultaneous determining E3810 enantiomers and their metabolites by using flavoprotein-conjugated columnJ. Pharm. Sci.85903907CrossRefPubMedGoogle Scholar
  13. 13.
    Abelo, A., Andersson, T. B., Antonsson, M., Naudot, A. K., Skanberg, I., Weidolf, L. 2000Stereoselective metabolism of omeprazole by human cytochrome P450 enzymesDrug Metab. Dispos.28966972PubMedGoogle Scholar
  14. 14.
    Arimori, K., Yasuda, K., Katsuki, H., Nakano, M. 1998Pharmacokinetic differences between lansoprazole enantiomers in ratsJ. Pharm. Pharmacol.5012411245PubMedGoogle Scholar
  15. 15.
    Masa, K., Hamada, A., Arimori, K., Fujii, J., Nakano, M. 2001Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogsBiol. Pharm. Bull.24274277CrossRefPubMedGoogle Scholar
  16. 16.
    Kim, K. A., Kim, M. J., Park, J. Y., Shon, J. H., Yoon, Y. R., Lee, S. S., Liu, K. H., Chun, J. H., Hyun, M. H., Shin, J. G. 2003Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymesDrug Metab. Dispos.3112271234CrossRefPubMedGoogle Scholar
  17. 17.
    Abelo, A., Andersson, T. B., Bredberg, U., Skanberg, I., Weidolf, L. 2000Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazoleDrug Metab. Dispos.285864PubMedGoogle Scholar
  18. 18.
    Masubuchi, N., Yamazaki, H., Tanaka, M. 1998Stereoselective chiral inversion of pantoprazole enantiomers after separate doses to ratsChirality10747753CrossRefPubMedGoogle Scholar
  19. 19.
    Hirayama, H., Xu, X., Pang, K. S. 1989Viability of the vascularly perfused, recirculating rat intestine and intestine–liver preparationsAm. J. Physiol.257G249G258PubMedGoogle Scholar
  20. 20.
    Ernster, L., Siekevitz, P., Palada, G. E. 1962Enzyme–structure relationships in the endoplasmic reticulum of rat liverJ. Cell Biol.15541562CrossRefGoogle Scholar
  21. 21.
    Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J. 1951Protein measurement with the folin phenol reagentJ. Biol. Chem.193175265PubMedGoogle Scholar
  22. 22.
    Yanaoka, K., Tanigawara, Y., Nakagawa, T., Iga, T. 1981A pharmacokinetic analysis program (MULTI) for microcomputerJ. Pharmacobio-Dyn.4879885PubMedGoogle Scholar
  23. 23.
    Zhong, D. F., Xie, Z. Y., Chen, X. Y. 2005Metabolism of pantoprazole involving conjugation with glutathione in ratsJ. Pharm. Pharmacol.57341349CrossRefPubMedGoogle Scholar
  24. 24.
    Xie, Z. Y., Yang, B. H., Zhang, Y. F., Zhong, D. F. 2004Studies on chiral inversion of dextro-pantoprazole in humanActa Pharm. Sin.39370373Google Scholar
  25. 25.
    Mano, N., Oda, Y., Takakuwa, S., Yuzuriha, T., Mano, N., Asakawa, N. 1996Plasma direct injection high-performance liquid chromatographic method for simultaneously determining E3810 enantiomers and their metabolites by using flavoprotein-conjugated columnJ. Pharm. Sci.85903907CrossRefPubMedGoogle Scholar
  26. 26.
    Stenhoff, H., Blomqvist, A., Lagerstrom, P. O. 1999Determination of the enantiomers of omeprazole in blood plasma by normal-phase liquid chromatography and detection by atmospheric pressure ionization tandem mass spectrometryJ. Chromatogr., B734191201Google Scholar
  27. 27.
    Huber, R., Kohl, B., Sachs, G., Senn-Bilfinger, J., Simon, W. A., Sturm, E. 1995The continuing development of proton pump inhibitor, with particular reference to pantoprazoleAliment. Pharmacol. Ther.9363378PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Zhiyong Xie
    • 1
  • Yini Zhang
    • 1
  • Haiyan Xu
    • 1
  • Dafang Zhong
    • 1
  1. 1.Laboratory of Drug Metabolism and PharmacokineticsShenyang Pharmaceutical UniversityShenyangPeople's Republic of China

Personalised recommendations